Microglial CD44 expression is elevated following stroke (Sawada et al., 2020), ALS (Sawada et al., 2020), glioma (Du et al., 2022), and Alzheimer’s disease (Rangaraju et al., 2018). This evidence concerns the gene CD44 and central nervous system cancer.